Skip to main content
Research · Market Access

Medicare just created a payment category for clinical AI, Software as a Medical Service (SaMS)

The CY 2027 OPPS and PFS final rules created SaMS and the O1 status indicator. What Medicare pays for diagnostic AI, by disease category.

Erik Abel, PharmD, MBA · November 2026 · 16 min read

Market Access AI Diagnostics Reimbursement Medicare Digital Health

Key Takeaways

  • CMS prices medical AI by modality tier, not by algorithm value, and the 2027 rule carries that hierarchy intact into the new "O1" category. CT and angiography AI sit near $650 to $950, echo AI at $350, ECG and EEG AI near $150, and retinal and facial-phenotype AI at $75.50.
  • "O1" means separate payment, including on a same-day procedure claim. Codes left at "Q1" still bundle when a significant procedure shares the claim, and codes at "Q4" still bundle on the laboratory side, so the status indicator decides who gets paid that day.
  • Fourteen genomic and digital-pathology codes left the laboratory fee schedule for outpatient and physician payment under "O1." Eight appear in this dataset and all gain separate payment. The lupus, IBD, and colorectal lab codes did not move.
  • Moving to "O1" froze the rate at the New Technology band while clinical APC rates rose, so a code that stayed status "S" often kept more annual upside than one that moved. The pathology codes are the exception, since they went from packaged to $750.50 paid on their own.
  • FDA authorization is the entry ticket, but defensible HEOR is the table stakes. Burn classification and EEG analysis became payable once cleared, while cardiac MR perfusion AI and vertebral fracture AI stayed unpaid, and non-device clinical decision support was excluded.
  • CMS calls all of this interim. The permanent valuation method arrives no earlier than CY 2028, which is where the Health Tech Investment Act and the packaging question both return.

Medicare now has a new name and a payment home for medical AI. The CY 2027 final rules rename these tools Software as a Medical Service, give the separately paid ones a new status indicator called "O1," and move a set of algorithmic laboratory analyses off the laboratory fee schedule into outpatient and physician payment. For 2027 the dollars barely move, because CMS carried the old rates into fixed New Technology payment bands. What changed is the architecture. Which service gets paid on the same day as a procedure, and paid in full rather than discounted, which service sits on the coverage frontier, and which pays by imaging modality rather than by what the algorithm is worth.

What CMS actually did

On November 4, 2026, CMS issued the CY 2027 OPPS final rule (CMS-1850-FC) and the CY 2027 Physician Fee Schedule final rule (CMS-1848-F), both effective January 1, 2027. Inside them is a quiet renaming that carries real weight. CMS retired the term Software as a Service, which the rest of the technology world uses for cloud computing, and replaced it with Software as a Medical Service, SaMS, for software that supports clinical decision making through algorithmic analysis. The agency then gave the separately paid SaMS codes a new outpatient status indicator, "O1," which the rule defines as paid under the OPPS with separate APC payment.

CMS was explicit that this is a first step. It placed SaMS into New Technology APCs, the fixed-dollar payment bands the agency uses for services it is not yet ready to value through its normal cost methodology, and it said a fuller valuation approach will come in later rulemaking. The New Technology APC assignments were set to track the CY 2026 rates, so for 2027 the payment amounts are familiar. What changed is the plumbing beneath them.

Two caveats travel with every line of this. An APC assignment establishes how a service is paid if it is covered, not whether it is covered, and local Medicare contractors still decide medical necessity. Payment status is also not a coverage guarantee, so a code can carry an "O1" status indicator and a dollar figure and still face a coverage determination at the point of care.

This rule sets traditional Medicare payment only. Whether Medicare Advantage, Medicaid, and commercial payers adopt the same treatment is a separate question, and it will turn on each plan's view of a solution's integrated evidence, safety, quality, and health economics before they accept its value and merit.

How to read the money

The clearest pattern in the data is that CMS prices these tools by the modality they run on, not by what the algorithm contributes. A plaque-quantification algorithm on a CT sits near $950. An echo heart-failure algorithm sits at $350. An ECG or EEG algorithm sits near $150. A retinal or facial-phenotype algorithm sits at $75.50. The software in each case is a single-purpose classifier, yet the payment tracks the cost of the underlying image or signal rather than the clinical lift of the analysis. The 2027 rule carried that hierarchy straight into the New Technology bands.

The rates themselves tell a second story that only the primary data reveals. The New Technology APC bands held flat from 2026 to 2027, while the clinical APC rates rose with the annual update. APC 5734, the ECG and acoustic home, went from $135.93 to $149.81. APC 5733 went from $60.27 to $65.60. APC 5743, the echo home, went from $313.79 to $353.67. A code that moved into "O1" froze at its band amount, so 0932T is worth $350.50 under "O1" where it would have reached $353.67 had it stayed in its clinical APC. The difference is small this year, and the point is the mechanism. Moving into the SaMS home trades the annual-update path for separate payment. For most imaging codes that is a fair trade. For the pathology codes it is a clear win, because they moved from packaged on the laboratory schedule to $750.50 paid on their own.

Same-day packaging and separate payment

These algorithms operationally sit on top of a procedure performed the same day, an AI analysis applied to a CT, an echo, or an MRI done in the same encounter. The worry across AI MedTech was that Medicare would treat the algorithm as a second procedure on the claim and cut its payment, the way the OPPS discounts multiple procedures. The final rule answers that worry. A service's status indicator decides whether it is paid on its own or folded into another service, and "O1" is the separately paid status with no multiple-procedure discount. New Technology APCs are also exempt from the comprehensive-APC packaging that sweeps many outpatient services into one bundled payment, and Addendum D1 defines "O1" as separate APC payment. So an "O1" algorithm applied to a same-day CT, echo, angiogram, or ECG is a separate line, paid in full. That is the headline result for imaging and cardiology AI.

The exceptions are where the money leaks. 0902T, the QTc algorithm, stayed at "Q1," which pays separately only when no significant procedure shares the claim and otherwise bundles. The lupus, IBD, and colorectal lab codes stayed at "Q4," the conditionally packaged laboratory status, which pays on the laboratory schedule only when the code is alone on the claim and otherwise bundles into the visit or procedure. The "E1" status indicator codes pay nothing at all. The eight pathology codes that moved from "Q4" to "O1" are the cleanest same-day winners, since they went from bundled to guaranteed separate payment regardless of what else is on the claim.

The disease-category map

software as a medical service(SaMS, n.)

Medicare's CY 2027 term for software that supports clinical decision making through algorithmic analysis, paid under the outpatient and physician fee schedules. The separately paid outpatient codes carry a new status indicator, "O1," meaning paid under the OPPS with separate APC payment.

The table below reads each code from its CY 2026 baseline into its CY 2027 result. Every 2027 value is drawn from the CMS CY 2027 final Addenda. Filter by disease category or by how the code is paid, search by code or function, and switch on technical detail to see the status indicators and APCs. Vendor names are representative examples only.

Category
Paid
CategoryCodeFunctionRepresentative usePayment status2027 payment 2026 SI / APC / rate2027 SI / APC / rate
Cardiology0932TAugmentative echo analysis estimating heart failureUltromics EchoGo HFPaid separately$350.50S / 5743 / $313.79O1 / 1505 / $350.50
Cardiology75580Software FFR estimate from coronary CT angiographyHeartFlow and peersPaid separately$850.50S / 5724 / $877.34O1 / 1510 / $850.50
Cardiology1086T / 1087TAugmentative angio-derived coronary fractional flowVendor unconfirmedPaid separately$850.50S / 5724 / $877.34O1 / 1510 / $850.50
Cardiology75577Coronary plaque quantification on CTCleerly, HeartFlow, ElucidPaid separately$950.50S / 1511 / $950.50O1 / 1511 / $950.50
Cardiology0897TNoninvasive augmentative arrhythmia analysisVektor vMapPaid separately$850.50S / 5724 / $877.34O1 / 1510 / $850.50
Cardiology0764T / 0765TAssistive ECG risk assessmentAnumana, Tempus, Viz.aiPaid separately$150.50S / 5734 / $135.93O1 / 1503 / $150.50
Cardiology0902TAugmentative QTc from ECGAliveCorBundled same-day$149.81Q1 / 5734 / $135.93Q1 / 5734 / $149.81
Cardiology0962TAssistive combined acoustic and ECGEkoPaid separately$149.81S / 5734 / $135.93S / 5734 / $149.81
Cardiology1104TNoninvasive cardiopulmonary assessment for CADCorVistaPaid separately$150.50S / 5734 / $135.93O1 / 1503 / $150.50
Cardiology0716TCardiac acoustic waveform for CAD riskAcarix CADScorPaid separately$65.60S / 5733 / $60.27S / 5733 / $65.60
Cardiology0899T / 0900TAugmentative cardiac MR blood flowModality-genericNot paid yetNot payableE1 / not payableE1 / not payable
Pulmonary0877T / 0878TAugmentative chest CT for interstitial lung diseaseImvaria and alternatesPaid separately$650.50S / 1508 / $650.50O1 / 1508 / $650.50
Imaging, multi-organ0721T / 0722TQuantitative CT tissue characterizationOptellum and othersPaid separately$650.50S / 1508 / $650.50O1 / 1508 / $650.50
Imaging, hepatobiliary0723T / 0724TQuantitative MRCPPerspectum MRCP+Paid separately$950.50S / 1511 / $950.50O1 / 1511 / $950.50
Oncology imaging1085TAssistive metastatic lesion ID on PET/CTAIQ TRAQinformPaid separately$850.50S / 5724 / $877.34O1 / 1510 / $850.50
Digital pathology0414ULung whole-slide H&E, multi-geneVendor unconfirmedPaid separately$750.50Q4 / CLFSO1 / 1509 / $750.50
Digital pathology0418UBreast H&E, recurrence scorePreciseDxPaid separately$750.50Q4 / CLFSO1 / 1509 / $750.50
Digital pathology1063T / 1064TBladder H&E histomorphologyValar VestaPaid separately$750.50Q4 / CLFSO1 / 1509 / $750.50
Digital pathology1097TPancreas H&E, chemo responseValar VitaraPaid separately$750.50Q4 / CLFSO1 / 1509 / $750.50
Digital pathology1106TBreast H&E, metastasis riskArteraPaid separately$750.50Q4 / CLFSO1 / 1509 / $750.50
Digital pathology1107TProstate H&E, metastasis and mortality riskVendor unconfirmedPaid separately$750.50Q4 / CLFSO1 / 1509 / $750.50
Oncology lab AI0220UAI breast image analysis, risk scorePreciseDxPaid separately$750.50Q4 / CLFSO1 / 1509 / $750.50
Oncology lab AI0261UAI colorectal image analysisVeracyte ImmunoscoreOn lab scheduleLab scheduleQ4 / CLFSQ4 / CLFS
Neurology1041TAugmentative EEG waveform analysisNeuroMatchPaid separately$150.50S / 5734 / $135.93O1 / 1503 / $150.50
Neuro / MSK0691TAutomated vertebral fracture analysis on CTModality-genericNot paid yetNot payableE1 / not payableE1 / not payable
Behavioral healthG0685Algorithm assessment for autismCognoa Canvas DxPaid separately$150.50S / 5734 / $135.93O1 / 1503 / $150.50
Psychiatry / neuromod0889T; 0890T-0892TrTMS target development; treatment daysMagnus SAINTPaid separately$950.50; $3,750.50S / 1511; 1525 / $950.50; $3,750.50S / 1511; 1525 / $950.50; $3,750.50
Ophthalmology92229Point-of-care automated retinal analysisLumineticsCore, EyeArt, AEYEPaid separately$75.50S / 5733 / $60.27O1 / 1502 / $75.50
Dermatology / genetics0731TAugmentative facial phenotype analysisFace2GenePaid separately$75.50S / 5733 / $60.27O1 / 1502 / $75.50
Wound / burn0972TAssistive burn healing classificationDeepViewPaid separately$250.50E1 / not payableO1 / 1504 / $250.50
Autoimmune lab (SLE)0062U, 0312U, 0446U, 0447UAI lupus analysesVeracis, Exagen, ProgentecOn lab scheduleLab scheduleQ4 / CLFSQ4 / CLFS
GI lab (IBD)0203UAI IBD analysisPredictSURE IBDOn lab scheduleLab scheduleQ4 / CLFSQ4 / CLFS
No codes match these filters.

Payment status reads the CY 2027 status indicator in plain terms. "Paid separately" covers "O1" and "S," "Bundled same-day" covers "Q1" and "Q4," and "Not paid yet" is "E1." The vendor column names representative examples, not exclusive assignments, since these codes are written by function and more than one solution can fit a code today or in the future. CPT codes are referenced by number with original functional descriptions. CPT copyright American Medical Association, all rights reserved. Payment is not coverage.

Who left the laboratory fee schedule, and who did not

The most consequential single move is the reclassification of fourteen algorithmic laboratory analyses. CMS decided that a stand-alone algorithm run on data a laboratory already generated is not a laboratory test. Its reasoning is that a genomic sequence is produced once, and the later algorithmic analyses of that sequence can run an unlimited number of times, often by an entity that performs no wet-lab work and may not even meet the regulatory definition of a laboratory. On that logic CMS treats these analyses as other diagnostic tests under section 1861(s)(3) of the Act and pays them under the OPPS and the physician schedule rather than the Clinical Laboratory Fee Schedule.

The list grew from ten in the proposed rule to fourteen in the final. CMS added the exome and genome re-evaluation codes 81417 and 81427 and removed two codes, 0511U and 81416, that include real wet-lab work and therefore stay on the laboratory schedule. Of this dataset, eight codes made the move to "O1" at $750.50. The lupus, IBD, and colorectal analyses did not, so they remain conditionally packaged laboratory codes.

The move is not free for the codes that made it. Laboratory tests on the CLFS carry no beneficiary cost-sharing. Other diagnostic tests do, so a patient now owes coinsurance on an analysis that used to cost nothing to them at the point of care. The codes also escape the laboratory 14-day date-of-service rule, which changes who bills and when, and they enter payment systems built on budget neutrality that the laboratory schedule never had. CMS acknowledged the cost-sharing concern and proceeded anyway, and it declined to wait for the pending CLIA inquiry into whether these dry-lab analyses need laboratory certification at all.

The coverage frontier

A handful of codes mark the edge of what Medicare will pay for. Cardiac MR perfusion AI, 0899T and 0900T, and automated vertebral fracture analysis, 0691T, stayed at "E1," not payable. They are not denied on clinical grounds. They sit outside a payable benefit category or lack the FDA authorization that the rule treats as the entry ticket.

That entry ticket is explicit. Several codes crossed from "E1" to "O1" in this cycle once they carried FDA authorization, including burn-healing classification, 0972T, now paid at $250.50, and the EEG analysis 1041T. CMS also drew a hard line around non-device clinical decision support, which it excluded from SaMS entirely, so a pure decision-support algorithm that ranks treatment options from prior results stays outside the category. For a developer, the map reads as a sequence, clear the FDA, land in a payable category, then position for separate payment.

For a product developer, this reopens the usual sequence of market requirements, then product requirements, then commercial planning. It argues for embedding integrated evidence, market access, and HEOR planning much earlier in the strategy cycle, alongside regulatory, to improve speed to market and align with the payer and provider business models the product will meet.

One gap is worth naming for cardiology. There is no dedicated code today for left-ventricular filling-pressure estimation, the function behind several emerging heart-failure tools, and no code for some of the newer echo decision-support products. Until a code exists, these tools have no payment path, which is the step before the fee-for-service frontier.

The physician side

The physician schedule mirrors the outpatient logic with its own mechanics. CMS proposed to let each Medicare contractor price the laboratory SaMS analyses, then dropped that after comment in favor of national pricing crosswalked to the outpatient rates, with active status. The result tracks the facility payment and then drifts with geography and the conversion factor over time.

The physician fee schedule does not pay in dollars directly. It pays in relative value units. Every service carries three kinds of RVU, one for physician work, one for practice expense, and one for malpractice. Medicare adds them, adjusts for local cost differences, and multiplies by a fixed dollar conversion factor to reach the payment. The work RVU stands for the clinician's time, skill, and effort. The practice-expense RVU stands for the cost of delivering the service, meaning staff, equipment, and overhead.

For SaMS, CMS did something telling. It took the outpatient payment, divided it by the CY 2027 conversion factor to produce a practice-expense RVU, and assigned no physician work RVU at all. Medicare is paying for the cost of running the software, not for physician labor, which fits a service where the work is the software rather than the clinician.

The open question ahead is whether, as these tools prove efficiency gains, CMS revisits the physician work RVUs of the underlying services the AI assists. Budget neutrality, and in some cases outright reductions, remain CMS's goal, and other payers tend to apply the same lens.

One further physician-side change sits adjacent to all of this. The CY 2027 PFS final rule makes electronic prior authorization mandatory within the Ambulatory Specialty Model, beginning with the 2028 performance year, when both the electronic prior authorization measure and a new electronic prior authorization measure for prescription drugs become required under the model's health information exchange objective. It is not a program-wide mandate, and it should be read at that scope, but it signals where prior authorization is heading for the specialties that use these tools most.

What is still unsettled

CMS repeated the word interim throughout, and the open questions are substantive. The permanent valuation method for SaMS arrives no earlier than CY 2028, and nothing guarantees that "O1" keeps paying like a separately paid procedure. CMS built "O1" as a single label across imaging, cardiology, and laboratory AI, which gives it one lever to pull later. If it decides to discount, package, or revalue software, it can redefine "O1" once rather than re-sorting dozens of codes.

Two outside forces press on the same timeline. The Health Tech Investment Act, S.1399 and H.R.6197, would create a Medicare payment pathway for FDA-authorized AI devices, assigning them New Technology APC treatment for a set period with payment informed by manufacturer cost data. The bill sits in committee without recorded action, so it is a signal rather than a certainty. Separately, the ONC HTI-5 rule, finalized in late October 2026, rolled back the earlier HTI-1 transparency requirements for predictive decision-support software, which removes a disclosure obligation at the same moment CMS is standing up payment for these tools.

There is also a conceptual fault line worth calling out, because it will drive the next round of billing code design. CMS treats physical work as disqualifying for a laboratory SaMS code, so an analysis that includes staining or an assay stays on the laboratory schedule, while it treats physical work as perfectly compatible with SaMS outside the laboratory, where an autonomous retinal camera or an EEG acquisition counts as SaMS despite acquiring its own data. The result is less a coherent definition of software than a map of Medicare's historical payment silos. For a developer, the boundary is now a design choice, since where the physical step sits in the code can decide cost-sharing, the date-of-service rule, and eventual packaging.

Erik's Hot Take

Medicare did the pragmatic thing and the revealing thing at once. The pragmatic thing is a holding pattern, a named category, a separate-payment status, and rates crosswalked from last year, which buys time without disrupting anyone's economics in 2027. The revealing thing is what the holding pattern assumes. By pricing every algorithm through the modality it rides on, CMS has said, for now, that it does not know how to value the software itself, so it is paying for the pipe and letting the intelligence ride along. That is defensible as a first step and untenable as a destination, because the clinical and economic value of these tools has little to do with whether the underlying image is a CT or an echo.

The piece of this that deserves attention is the status indicator, not the dollar figure. "O1" is one lever that now governs separate payment for an entire class of software, and the same rule that created it kept the power to discount or package it later. Developers and health systems that treat 2027 as settled will be the ones surprised by CY 2028. The ones who read "O1" as a placeholder, and who put their evidence into the valuation debate now, while CMS is openly asking how to price software, are the ones who will shape where the permanent number lands. The white space here is the valuation method itself, and it is still unwritten.

This also sets the table for new business models in MedTech. The industry can move past selling feature-rich hardware alone, toward a hybrid path that sells the capital equipment and commercializes the AI software separately, on licensed seats or utilization-based terms. A durable SaMS payment line is what makes that shift bankable.

Frequently asked questions

What is Software as a Medical Service?
It is Medicare's CY 2027 term for software that supports clinical decision making through algorithmic analysis, finalized in the OPPS and Physician Fee Schedule final rules. It replaces the older Software as a Service label to avoid confusion with general cloud computing.
What is the O1 status indicator?
O1 is a new outpatient status indicator for separately paid Software as a Medical Service. Addendum D1 defines it as paid under the OPPS with separate APC payment, and CMS set it to pay like a significant procedure, with no multiple-procedure discounting.
Does a SaMS algorithm get paid on the same day as the procedure it runs on?
If it carries O1, yes. O1 codes sit in New Technology APCs that are exempt from comprehensive packaging, so they pay separately even on a same-day procedure claim. Codes left at Q1 or Q4 still bundle when another service shares the claim.
Which laboratory tests moved off the Clinical Laboratory Fee Schedule?
Fourteen algorithmic analyses, mostly genomic re-evaluation and digital-pathology codes, moved to outpatient and physician payment as other diagnostic tests. CMS removed two codes with wet-lab steps and added the exome and genome re-evaluation codes. The lupus, IBD, and colorectal analyses stayed on the laboratory schedule.
Did the 2027 rule raise or cut payment for medical AI?
Neither, for the most part. The New Technology bands were crosswalked from 2026, so the dollars barely move. The real change is the payment status, which determines separate payment and same-day treatment, and the reclassification of some laboratory analyses, which adds beneficiary cost-sharing.
Does this apply to Medicare Advantage, Medicaid, and commercial payers?
No. The OPPS and Physician Fee Schedule set traditional Medicare payment only. Whether Medicare Advantage, Medicaid, and commercial payers adopt the same treatment is a separate question, and it will turn on each plan's view of a solution's integrated evidence, safety, quality, and health economics.
What does the physician fee schedule pay for these services?
National pricing crosswalked from the outpatient rates, at active status. The value is built entirely from practice-expense relative value units, equal to the outpatient payment divided by the conversion factor, with no physician work value.
What is still undecided after this rule?
The permanent valuation method, which arrives no earlier than CY 2028, and whether O1 keeps paying separately or is later discounted or packaged. The Health Tech Investment Act and the CLIA dry-lab inquiry both bear on the same timeline.

Sources

  • CMS, Calendar Year 2027 OPPS and ASC Final Rule (CMS-1850-FC), Fact Sheet, November 4, 2026.
  • Federal Register, CY 2027 OPPS Final Rule, document 2026-22739, November 6, 2026.
  • Federal Register, CY 2027 Physician Fee Schedule Final Rule (CMS-1848-F), document 2026-22743, November 9, 2026.
  • CMS, CY 2027 OPPS Final Rule Addendum A (APC payment rates), Addendum B (HCPCS payment), and Addendum D1 (status indicators), updated November 10, 2026.
  • CMS, October 2026 OPPS Addendum B, CY 2026 baseline payment rates.
  • Reed Smith, CMS Finalizes Interim Payment Policy for Software as a Medical Service, November 2026.
  • Bruce Quinn, Discoveries in Health Policy, CMS Pulls Algorithmic Lab Tests Off the CLFS, November 2026.
  • Holland and Knight, Health Dose, November 10, 2026.
  • American College of Cardiology, summary of the CY 2027 PFS and OPPS final rules, November 2026.
  • AMA, CPT Appendix S, AI taxonomy (assistive, augmentative, autonomous).
  • Congress.gov, Health Tech Investment Act, S.1399 and H.R.6197.
  • HHS and ONC, HTI-5 final rule, October 2026.

Method and verification. The CY 2026 baseline was taken from the October 2026 OPPS Addendum B. Every CY 2027 status indicator, APC, and payment rate was verified directly against the CMS CY 2027 final Addendum A, Addendum B, and Addendum D1. The physician-side provisions were verified against the Federal Register text of the CY 2027 PFS final rule. Product mappings are representative and non-exclusive, drawn from FDA, manufacturer, and coding sources. CPT codes are referenced by number with original functional descriptions rather than reproduced CPT descriptor text.

This piece is analysis and commentary based on public sources and professional experience as of the date noted, and nothing in it constitutes legal, clinical, or financial advice. Payment descriptions reflect the CMS rules and addenda cited and apply to traditional Medicare only. An APC assignment and payment rate establish how a service may be paid if covered, not whether it is covered. Product references are market examples and their inclusion implies no endorsement. Interpretive conclusions are the author's opinion. All views reflect independent professional judgment and do not represent the views of any current or former employer or affiliated organization.

Working on a payment path for medical AI?

I take a small number of advisory engagements, board seats, and speaking invitations each year.

Start a Conversation More Research